News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Epigenomics AG Reports Results for Financial Year 2016

PDF Berlin (Germany) and Germantown, MD (U.S.A.), April 26, 2017 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY), or the “Company”, today announced its financial results for the year ended December 31, 2016. Financial results ·     In 2016, Epigenomics’ total revenue increased by 102% to EUR 4.2 million (2015: EUR 2.1 million), exceeding previous year’s figure […]

Read more

Blitz F16-83 GmbH to launch takeover offer for Epigenomics AG

PDF Shareholders will be offered 7.52 Euros in cash per share valuing Epigenomics at approximately 171 million Euros The offer reflects a 49.4% premium to 3-month volume weighted average share price prior to announcement and a 32.0% premium to the highest closing price in the last 12 months Voluntary public takeover offer will be for […]

Read more

Epigenomics AG: U.S. Department of Veterans Affairs awards supply contract for Epi proColon®

PDF Berlin (Germany) and Germantown, MD (U.S.A.), March 3, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), today announced that the U.S. Department of Veterans Affairs has awarded Epigenomics’ distribution partner Polymedco, Inc. with a five-year supply contract for Epi proColon, commencing March 1, 2017. Epi proColon is an FDA approved, blood-based test […]

Read more

Epigenomics Joins Forces with hundreds of Organizations to Increase Colorectal Cancer Screening Rates in the United States

PDF “80% by 2018” is a shared goal to have 80% of adults aged 50 and older screened for colorectal cancer by 2018 – Colorectal cancer screening has been proven to save lives Berlin (Germany) and Germantown, MD (U.S.A.), February 27, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), today announced that it […]

Read more

Journal of Molecular Diagnosis & Therapy publishes review of blood-based screening test Epi proColon® 2.0 CE

PDF Liquid biopsy test delivers high sensitivity and specificity and may increase participation in cancer screening programs Berlin (Germany) and Germantown, MD (U.S.A.), February 14, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that an independent, peer-reviewed article on its blood-based colorectal cancer screening test Epi proColon 2.0 CE was published in the […]

Read more

Epigenomics AG: Systematic study review supports use of Epi proColon® in blood-based cancer detection

PDF Meta-analysis published in renowned journal “Clinical and Translational Gastroenterology” Berlin (Germany) and Germantown, MD (U.S.A.), January 30, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that the scientific results of a recent systematic review and meta-analysis of clinical studies with Epi proColon were published in “Clinical and Translational Gastroenterology”, a journal of […]

Read more
......